Molecular Diagnostics in Early Detection of Cancer

The early detection of cancer is expected to significantly improve patient survival rates. In this context, liquid biopsy offers a simple and fast method to detect cancer and monitor disease status or response to treatment. Generally, mutations in circulating DNA (ctDNA) are used to detect the presence of cancer or follow cancer evolution. Our hypothesis is that not only genetic but also epigenetic biomarkers can be used for the early identification of patients with cancer.

Contact: Dr. rer. nat. Claudia Paret

Project relevant Publications:

Maximilian Sprang , Claudia Paret, Joerg Faber. CpG-Islands as Markers for Liquid Biopsies of Cancer Patients Cells, 2020 Aug 1;9(8):1820. doi: 10.3390/cells9081820.